TCTR20220615009尚未招募2 期
Single fraction of proton stereotactic body radiotherapy (SBRT) versus multiple fraction of photon SBRT for bone metastatic patients
Radiation oncology division, Radiology Department, KCMH0 个研究点目标入组 136 人开始时间: 2022年6月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1.Patients with a pathologic diagnosis of malignancy
- •2.Aged older than 18 years old
- •3.Patients with any radiographic evidence of bone metastases, including plain x-ray, bone scan, CT scan , MRI scan or PET scan
- •4.Patients with spine and non-spine lesions
- •5.With pain or dysathesia ( Pain score of at least 2 on the scale)
- •6.Patients with a life expectancy of more than 3 months
- •7.Patients with solitary or oligometastatic or bone- only metastatic disease
- •8.Patients who are able to complete NPRS scores and the questionnaire of Quality of life
- •9.Patients with no more than 3 separate radiation treatment fields concurrently
- •10.Patients with surgery for osseous metastases allowed
- •11.Patients with gross residual disease or high risk for recurrence after surgery
- •12.Patients with prior conventional beam radiation therapy to the treatment site ( more than 90 days after radiation)
- •13.Patients with spinal cord compression after decompressive surgery
排除标准
- •-Patients with radiosensitive tumor such as malignant melanoma
- •-Patients with a pathologic fracture to the treatment site who needs surgery (spinal instability or neurologic deficit resulting from bony fragments)
- •-Patients with spinal canal compromise >25%
- •-Patients with tumor location within 5 mm of spinal cord or caudal equina
- •-Patients who cannot perform spinal MRI with any reasons such as pacemaker
- •-Patients with chemotherapy within 30 days before SBRT
- •-Patients who have systemic radionuclide delivery within 30 days before SBRT
- •-Patients who have previous SBRT
研究者
相似试验
进行中（未招募）
1 期
Combined hypofractionated stereotactic body radiotherapy with immunomodulating systemic therapy for inoperable recurrent head and neck cancer.local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx in previously irradiated tissue, with former irradiation with curative intent.EUCTR2017-000133-31-BEZ Gent30
已完成
不适用
Stereotactic fractionated radiotherapy of the resection cavity as adjuvant treatment after resection of brain metastasesC71Malignant neoplasm of brainDRKS00009357niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde60
尚未招募
不适用
Effectiveness of radical stereotactic body radiotherapy for vertebral bone metastasisThe patients with vertebral bone metastasisJPRN-UMIN000045898Asahi University20
招募中
1 期
Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate cancer. Phase II Spanish study, prospective, multicenter. (OLIGORESIST)Oligometastatic patients with castration-resistant prostate cancerCTIS2023-505024-62-01Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT)51
进行中（未招募）
1 期
Addition of stereotactic body radiotherapy (SBRT) to chemotherapy in locally advanced biliary tract cancersocally advanced biliary tract cancerMedDRA version: 21.0Level: LLTClassification code 10004586Term: Bile duct adenocarcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2014-003656-31-GBniversity College London81